問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

葉昭廷Yeh, Chau-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • chauting@cgmh.org.tw

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉昭廷

List

40Cases

2017-10-16 - 2019-05-31

Phase I

A RANDOMIZED, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7062931 WITH SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND MULTIPLE DOSES AND MODIFIED REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

  • Condition/Disease

    CHRONIC HEPATITIS B VIRUS INFECTION

  • Test Drug

    RO7062931 sterile liquid for inection

Participate Sites
5Sites

Terminated4Sites

2016-04-29 - 2019-04-28

Phase I

A MULTIPLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE AND MULTIPLE-ASCENDING DOSE, ADAPTIVE PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7020322 FOLLOWING ORAL ADMINISTRATION IN HEALTHY SUBJECTS AND CHRONIC HEPATITIS B PATIENTS

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    RO7020322

Participate Sites
5Sites

Terminated4Sites

2012-11-01 - 2016-02-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2023-10-01 - 2026-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2009-06-01 - 2012-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-02-01 - 2013-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-06-15 - 2010-12-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-07-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-12-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    1.Tenofovir Alafenamide (TAF, GS-7340)、 2.Tenofovir Disoproxil Fumarate (TDF, Viread®)

Participate Sites
11Sites

Terminated11Sites

2011-06-01 - 2014-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB